Wall Street Zen Downgrades AtriCure to Buy

Research firm cites concerns over the medical device company's outlook

Mar. 31, 2026 at 5:08am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, interlocking mechanical components in a heavy industrial banking machine, conveying a sense of institutional financial power and security.A recent wave of Wall Street downgrades on medical device firm AtriCure reflects growing concerns about the company's near-term outlook.Mason Today

Wall Street Zen has downgraded shares of AtriCure (NASDAQ:ATRC) from a strong-buy rating to a buy rating in a research note issued to investors. The move comes as several other research firms have also recently issued reports on AtriCure, with Oppenheimer, JPMorgan Chase & Co., and Zacks Research all lowering their ratings or price targets on the stock.

Why it matters

AtriCure is a leading medical device company focused on treatments for atrial fibrillation, a common heart rhythm disorder. The downgrade by Wall Street Zen and other firms suggests growing concerns about the company's near-term prospects, which could impact investor confidence and the stock price.

The details

In its research note, Wall Street Zen cited a number of factors behind the downgrade, including a recent price target cut by JPMorgan Chase & Co. from an 'overweight' rating to 'neutral' with a $36 price target. Oppenheimer also downgraded AtriCure from 'outperform' to 'market perform', while Zacks Research lowered its rating from 'strong-buy' to 'hold'.

  • Wall Street Zen issued the downgrade on Saturday, March 31, 2026.
  • Oppenheimer, JPMorgan Chase & Co., and Zacks Research all issued their reports in mid-February 2026.

The players

Wall Street Zen

A research firm that provides investment analysis and recommendations.

AtriCure

A medical device company focused on treatments for atrial fibrillation.

Oppenheimer

A financial services firm that provides research coverage on AtriCure.

JPMorgan Chase & Co.

A global financial services firm that provides research coverage on AtriCure.

Zacks Research

A research firm that provides investment analysis and ratings on public companies.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching AtriCure's upcoming earnings report and any further updates from research analysts on the company's outlook.

The takeaway

The downgrade by Wall Street Zen and other firms suggests growing concerns about AtriCure's near-term prospects, which could impact investor sentiment and the stock price. However, the company remains a leader in treatments for atrial fibrillation, and its long-term potential will depend on its ability to navigate the current challenges.